Search research articles
Contact Us
Filters
Showing results (191-200 of 257) with videos related to
Page
of 26
Sort By:
The Journal of Antimicrobial Chemotherapy
|
November 1, 1982
Ceftizoxime: collaborative multiphased in-vitro evaluation including tentative interpretive standards for disc susceptibility tests, beta-lactamase stability, and inhibition
A L Barry, R N Jones, C Thornsberry, et al.
Journal of Clinical Microbiology
|
January 1, 1989
Quality control limits for the standard anaerobic reference agar dilution susceptibility test procedure of the National Committee for Clinical Laboratory Standards
A L Barry, P C Fuchs, S D Allen, et al.
Burns : Journal of the International Society for Burn Injuries
|
February 25, 2022
The BUrn Mortality Prediction (BUMP) Score - An improved mortality prediction score based on data of the German burn registry
M Bagheri, P C Fuchs, R Lefering, et al.
The Journal of Antimicrobial Chemotherapy
|
January 1, 1996
Tentative interpretive criteria and quality control parameters for in-vitro susceptibility testing of Neisseria gonorrhoeae to two fluoroquinolones (PD 131628 and grepafloxacin (OPC 17116))
D L Sewell, A L Barry, S D Allen, et al.
Antimicrobial Agents and Chemotherapy
|
April 1, 1980
Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycin
R N Jones, P C Fuchs, H M Sommers, et al.
Diagnostic Microbiology and Infectious Disease
|
July 1, 1991
Antimicrobial activity of cefpirome. An update compared to five third-generation cephalosporins against nearly 6000 recent clinical isolates from five medical centers
R N Jones, M A Pfaller, S D Allen, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
|
August 1, 1992
Comparison of fixed concentration and fixed ratio options for testing susceptibility of gram-negative bacilli to piperacillin and piperacillin/tazobactam
M A Pfaller, A L Barry, P C Fuchs, et al.
Diagnostic Microbiology and Infectious Disease
|
November 1, 1986
In vitro activity of carumonam (RO 17-2301), BMY-28142, aztreonam, and ceftazidime against 7,620 consecutive clinical bacterial isolates
P C Fuchs, R N Jones, A L Barry, et al.
The Journal of Antimicrobial Chemotherapy
|
February 1, 1996
In-vitro susceptibility of Streptococcus pneumoniae to the d- and l-isomers of ofloxacin: interpretive criteria and quality control limits
A L Barry, P C Fuchs, S D Allen, et al.
The Journal of Antimicrobial Chemotherapy
|
November 1, 1995
Tests for susceptibility of Streptococcus pneumoniae to cefdinir: proposed interpretive criteria and quality control parameters for both microdilution and disc diffusion methods
P C Fuchs, A L Barry, F C Tenover, et al.
Page
of 26
Search research articles
Search
Showing results (191-200 of 257) with videos related to
Sort By:
Page
of 26
The Journal of Antimicrobial Chemotherapy
|
November 1, 1982
Ceftizoxime: collaborative multiphased in-vitro evaluation including tentative interpretive standards for disc susceptibility tests, beta-lactamase stability, and inhibition
A L Barry, R N Jones, C Thornsberry, et al.
Journal of Clinical Microbiology
|
January 1, 1989
Quality control limits for the standard anaerobic reference agar dilution susceptibility test procedure of the National Committee for Clinical Laboratory Standards
A L Barry, P C Fuchs, S D Allen, et al.
Burns : Journal of the International Society for Burn Injuries
|
February 25, 2022
The BUrn Mortality Prediction (BUMP) Score - An improved mortality prediction score based on data of the German burn registry
M Bagheri, P C Fuchs, R Lefering, et al.
The Journal of Antimicrobial Chemotherapy
|
January 1, 1996
Tentative interpretive criteria and quality control parameters for in-vitro susceptibility testing of Neisseria gonorrhoeae to two fluoroquinolones (PD 131628 and grepafloxacin (OPC 17116))
D L Sewell, A L Barry, S D Allen, et al.
Antimicrobial Agents and Chemotherapy
|
April 1, 1980
Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycin
R N Jones, P C Fuchs, H M Sommers, et al.
Diagnostic Microbiology and Infectious Disease
|
July 1, 1991
Antimicrobial activity of cefpirome. An update compared to five third-generation cephalosporins against nearly 6000 recent clinical isolates from five medical centers
R N Jones, M A Pfaller, S D Allen, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
|
August 1, 1992
Comparison of fixed concentration and fixed ratio options for testing susceptibility of gram-negative bacilli to piperacillin and piperacillin/tazobactam
M A Pfaller, A L Barry, P C Fuchs, et al.
Diagnostic Microbiology and Infectious Disease
|
November 1, 1986
In vitro activity of carumonam (RO 17-2301), BMY-28142, aztreonam, and ceftazidime against 7,620 consecutive clinical bacterial isolates
P C Fuchs, R N Jones, A L Barry, et al.
The Journal of Antimicrobial Chemotherapy
|
February 1, 1996
In-vitro susceptibility of Streptococcus pneumoniae to the d- and l-isomers of ofloxacin: interpretive criteria and quality control limits
A L Barry, P C Fuchs, S D Allen, et al.
The Journal of Antimicrobial Chemotherapy
|
November 1, 1995
Tests for susceptibility of Streptococcus pneumoniae to cefdinir: proposed interpretive criteria and quality control parameters for both microdilution and disc diffusion methods
P C Fuchs, A L Barry, F C Tenover, et al.
Page
of 26